A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

Inclusion Criteria:

• Have Body Mass Index (BMI) at screening of the following:

• 30 kilogram per square meter (kg/m2) OR

• 27 kg/m2 with at least one of the following weight-related health conditions atscreening:

• high blood pressure

• dyslipidemia

• obstructive sleep apnea, or

• heart disease

• Have a stable body weight (<5% body weight change) for 90 days prior to screening.

• Have a history of at least one self-reported unsuccessful dietary effort to reducebody weight

Exclusion Criteria:

• Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis,or abdominoplasty allowed if performed >1 year before screening)

• Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 monthsprior to screening)

• Have type 1 diabetes or type 2 diabetes

• Have had within 90 days prior to screening:

• heart attack

• stroke

• coronary artery revascularization

• unstable angina, or

• hospitalization due to congestive heart failure

• Have a history or diagnosis of New York Heart Association Functional ClassificationClass IV congestive heart failure

• Have taken medications or alternative remedies intended for weight loss within 90days of screening